Navigation Links
'Move to AMITIZA' Advertising Campaign Underscores the Power of Not Letting Chronic Constipation Slow People Down
Date:11/6/2007

Ads Creatively Depict the Predictable Relief Provided by the Only

Commercially Available Prescription Treatment for Chronic Idiopathic

Constipation in Adults

DEERFIELD, Ill., Nov. 6 /PRNewswire/ -- Takeda Pharmaceuticals North America, Inc. and Sucampo Pharmaceuticals, Inc. today announced the launch of the first direct-to-consumer (DTC) advertising campaign for AMITIZA(R) (lubiprostone), the only commercially available prescription treatment for Chronic Idiopathic Constipation in adults. The "Move to AMITIZA" campaign illustrates that the predictable relief (defined as 57%-63% had a spontaneous bowel movement within 24 hours with AMITIZA vs. 32%-37% with placebo) provided by AMITIZA may allow people living with chronic idiopathic constipation to move throughout their day without letting their condition slow them down.

"This is welcome news for the millions of Americans who live with Chronic Idiopathic Constipation," said Charles Baum, M.D., medical director, Gastroenterology at Takeda. "This condition remains largely under-treated, in part because only about one in four patients with Chronic Idiopathic Constipation ever visit a physician for treatment-either because people are embarrassed to talk about it, or because they may not be aware that prescription treatment options are available."

The ads, targeting women age 40 years and older, will run in various print and broadcast outlets and encourage people with Chronic Idiopathic Constipation to visit their doctor.

"Through our research, we learned that people with chronic constipation feel the condition slows them down," said Aimee Berner, marketing director, Gastroenterology at Takeda. "According to a nationwide survey conducted by Braun Research, 82 percent of women with chronic constipation have taken over- the-counter medications for relief; and nearly 60 percent of these women report that the treatments work only some of the time or not at all."

Constipation, one of the most common digestive complaints in the U.S., affects up to 42 million adults, and is more prevalent in women than men. Based on a retrospective analysis, it is estimated that 12 million can be characterized as suffering from Chronic Idiopathic Constipation. Chronic Idiopathic Constipation is chronic constipation with no known cause. Older adults age 65 years and older are especially susceptible to constipation.

AMITIZA, developed by Sucampo Pharmaceuticals, is the first and only chloride channel activator for the treatment of Chronic Idiopathic Constipation in adults, regardless of age or gender. AMITIZA has a unique mechanism of action that may provide predictable relief to help people with Chronic Idiopathic Constipation.

For additional background about AMITIZA and Chronic Idiopathic Constipation, please log onto http://www.amitizapresskit.com.

About AMITIZA(R) (lubiprostone) 24 mcg BID for Chronic Idiopathic Constipation

AMITIZA(R) (lubiprostone) is indicated for the treatment of Chronic Idiopathic Constipation in adults.

AMITIZA is contraindicated in patients with known mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be thoroughly evaluated by the treating physician to confirm the absence of such an obstruction prior to initiating AMITIZA treatment.

The safety of AMITIZA in pregnancy has not been evaluated in humans. In guinea pigs, lubiprostone has been shown to have the potential to cause fetal loss. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.

Patients taking AMITIZA may experience nausea. If this occurs, concomitant administration of food with AMITIZA may reduce symptoms of nausea. Patients who experience severe nausea should inform their physician.

AMITIZA should not be prescribed to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment and inform their physician if the diarrhea becomes severe.

In clinical trials, the most common adverse reactions (incidence > 4%) were nausea (29%), diarrhea (12%), headache (11%), abdominal pain (8%), abdominal distention (6%), and flatulence (6%).

For full prescribing information, visit http://www.amitiza.com.

AMITIZA(R) is a registered trademark of Sucampo Pharmaceuticals, Inc.

About Chronic Constipation

Constipation is one of the most common digestive complaints, and is the cause of 2.5 million visits to physicians and 92,000 hospitalizations annually. Constipation is defined as unsatisfactory defecation that is characterized by infrequent stools, difficult stool passage or both. Difficult stool passage includes: straining; hard or lumpy stools; difficulty passing stool; incomplete evacuation; prolonged time to stool; or the need for manual maneuvers to pass stool. Symptoms must persist for at least three consecutive months for the condition to be considered chronic.

Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., an emerging pharmaceutical company based in Bethesda, Md., focuses on the development and commercialization of drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The therapeutic potential of prostones was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding chief executive officer and advisor, international business development. Sucampo Pharmaceuticals' first product, AMITIZA(R) (lubiprostone), received marketing approval from the FDA in January 2006 for the treatment of Chronic Idiopathic Constipation in adults. To learn more about the company and its products, visit http://www.sucampo.com.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc., is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets products for diabetes, insomnia, wakefulness and gastroenterology. The company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc. and Sucampo
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. ConforMIS Moves Headquarters to Expanded Facilities in Burlington, MA
3. Mediatech Moves to Prince William County Innovation Park
4. FDA Removes Partial Hold on TELCYTA Clinical Development
5. Emisphere Technologies, Inc. Moves Into New Corporate Headquarters
6. BioSpace and BayBio Launch 11th Edition of Biotech Bay(TM) Hotbed Map Campaign
7. BioSpace, 2008 BIO International Convention and BIOCOM Launch 9th Edition of Biotech Beach Hotbed Map Campaign
8. Celebrities and Notables From the Worlds of Film, Television, Music and Sports Join Lifetime Televisions 13th Annual Multi-Platform Stop Breast Cancer For Life Campaign
9. Homewatch CareGivers Launches 2007 We Care For Veterans Campaign
10. BioStorage Technologies Becomes Green Powered through the Use of 100% Certified Renewable Energy
11. Nanowire generates power by harvesting energy from the environment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 12, 2016  PTC Therapeutics, Inc. (NASDAQ: ... (Strategies to Realize Innovation, Vision and Empowerment) grant ... provides funds to patient advocacy organizations to develop ... contributions to the rare disease community by increasing ... patient advocates. Mary Frances Harmon ...
(Date:2/11/2016)... Feb. 11, 2016  Vermillion, Inc. (NASDAQ: VRML ... today announced the formation of the Steering Committee for ... --> Pelvic masses can present physicians ... management. Once pregnancy is ruled out, pelvic masses may ... advanced endometriosis, benign ovarian tumors and gastrointestinal and urinary ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today ... Portland, Oregon -based community care ... provide population health analytics, quality reporting and care ... FamilyCare strengthen its team of quality managers, analysts ... to the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... BioInformant announces the February 2016 release of its ... and Technologies – Market Size, Segments, Trends, and Projections ... The first and only market research firm ... more than a decade of historical information on all ... type. This powerful 175 page global strategic report contains ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint Inhibitors ... Rising Market Are you interested in the ... revenues for checkpoint inhibitors. Visiongain,s report gives those ... product and national level. Avoid falling behind ... progress, opportunities and revenues those emerging cancer therapies ...
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)...  Glencoe Software, the world-leading supplier of image data ... provide the data management solution OMERO Plus for the ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of ... states such as health and disease, the presence or ...
Breaking Biology News(10 mins):